Time course of disease characteristics in subjects with severe allergic asthma starting treatment with omalizumab. Popov TA, Hristova D, Kralimarkova TZ, Mustakov TB, et al. Ann Allergy Asthma Immunol 2022 Jan 24. pii: S1081-1206(22)00024.

Read + Share

Amedeo Smart

Independent Medical Education

Popov TA, Hristova D, Kralimarkova TZ, Mustakov TB, et al. Time course of disease characteristics in subjects with severe allergic asthma starting treatment with omalizumab. Ann Allergy Asthma Immunol 2022 Jan 24. pii: S1081-1206(22)00024.
PMID: 35085820